Trust Logo - Return to the homepage

Introduction

Naloxone is an opioid antagonist licenced for use in:

  • Treatment of suspected acute opioid overdose or intoxication; and
  • Complete or partial reversal of central nervous system depression and especially respiratory depression, caused by natural or synthetic opioids

 

Scope

This policy is relevant to: Inpatient Pain Service, Supportive and Palliative care Service, Registered Nurses, Operating Department Practitioners (ODPs), Doctors, Non-Medical Prescribers, Pharmacy, Resuscitation Team, Outreach Team (not an exhaustive list).

 

Purpose

The purpose of this policy is to outline how to safely prescribe and administer naloxone to patients who have either acute opioid overdose or acute opioid respiratory depression and sedation in those receiving postoperative opioids, palliative care and in chronic opioid use.

 

Policy Details

Download: N/A
Compiled by: Harriet Barker, Lead Nurse Pain Services
Ratified by: Drugs and Therapeutics Committee
Date Ratified: March 2019
Date Issued: April 2019
Review Date: March 2022
Target Audience: All staff
Contact name: Harriet Barker, Lead Nurse Pain Services

 

See also:

  • Medicines Management Policy
  • Administration of Injectable Medicines Policy